(42) identified a tumour-specific neoantigen for BAP1 following insertion of a frameshift mutation translated into a truncated protein which was predicted to be presented by the patient’s HLA-B molecule as a tumour-specific neo-antigen. This evidence concerns the gene BAP1 and neoplasm.